Zacks.com on MSN4h
Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1 per share, missing the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.44 per share a year ago. These ...
Investor's Business Daily on MSN4h
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Neurocrine stock tumbled late Thursday after the company issued lackluster guidance for its bread-and-butter product, Ingrezza.Please watch the video at Investors.com - How To Buy Stocks: ...
Neurocrine: Q4 Earnings Snapshot
Neurocrine Biosciences Inc. NBIX) on Thursday reported fourth-quarter earnings of $103.1 million. The San Diego-based company said it had profit of $1 per share.
Neurocrine Biosciences Inc Q4 Profit Decreases, Misses Estimates
Neurocrine Biosciences Inc (NBIX) reported earnings for fourth quarter that decreased from the same period last year and missed the ...
Neurocrine reports Q4 adjusted EPS $1.69, consensus $1.93
Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...
Earnings Summary: Neurocrine Biosciences Q4
Neurocrine Biosciences missed estimated earnings by -1.0%, reporting an EPS of $1.69 versus an estimate of $1.71. Revenue was up $112.50 million from the same period last year. During the previous ...
American Association of Individual Investors6h
Which Is a Better Investment, Biogen Inc. or Neurocrine Biosciences, Inc. Stock?
Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.